Financial Performance - The company reported a total revenue of 100 million RMB for the first half of 2021, representing a year-on-year increase of 20%[15]. - The company's operating revenue for the first half of 2021 was approximately ¥906.9 million, representing a year-on-year increase of 10.79%[22]. - Future guidance estimates a revenue growth of 25% for the full year 2021, driven by new product launches and market expansion[15]. - Revenue increased due to heightened demand for molecular diagnostic products amid the ongoing COVID-19 pandemic, resulting in a sales growth of 60.80% year-on-year, with total revenue reaching approximately ¥263.44 million[81]. - Operating costs rose in line with revenue growth, totaling ¥263.44 million, reflecting a 60.80% increase compared to the previous year[81]. Profitability and Expenses - The gross profit margin improved to 60%, up from 55% in the same period last year[15]. - The net profit attributable to shareholders decreased by 9.59% year-on-year to approximately ¥386.8 million, primarily due to a decline in gross profit from COVID-19 testing reagent centralized procurement and increased sales and R&D expenses[22]. - Basic and diluted earnings per share decreased by 29.35% year-on-year to ¥2.07, influenced by the increase in share capital from the IPO[24]. - The net cash flow from operating activities dropped by 77.19% year-on-year to approximately ¥112.7 million, attributed to increased cash payments for goods and taxes[26]. Research and Development - Research and development expenses accounted for 10% of total revenue, reflecting the company's commitment to innovation[15]. - The R&D expenditure as a percentage of operating revenue rose by 1.61 percentage points to 3.61%, reflecting the company's commitment to technological innovation[24]. - R&D investment totaled approximately ¥32.78 million, a 99.94% increase compared to the previous period, with R&D expenses accounting for 3.61% of operating revenue, up by 1.61 percentage points[45][46]. - The company has developed over 400 products in molecular diagnostics, covering most legally mandated infectious diseases, and has received EU CE certification for several COVID-19 testing reagents[30]. Market Expansion and Product Development - User data indicates a 30% increase in active users, reaching 1.5 million by the end of June 2021[15]. - The company plans to launch two new products in Q3 2021, targeting a market expansion of 15% in the next fiscal year[15]. - The company is actively exploring international markets, with plans to enter Southeast Asia by the end of 2021[15]. - The company has established partnerships with three major hospitals to enhance its distribution network[15]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[15]. - The company faces risks from intensified market competition, particularly from multinational companies like Roche and Abbott, which dominate the high-end medical market[69]. - The company acknowledges the risk that the high growth in performance due to the COVID-19 pandemic may not be sustainable in the future[72]. - The company is subject to strict regulatory policies in the in vitro diagnostic industry, which may impact its operations if it fails to adapt to changes[71]. Corporate Governance and Shareholder Commitments - The company appointed Lü Liliang as the new General Manager after the resignation of Shao Junbin, who remains as Chairman and Director of the R&D Center[96]. - The actual controller and major shareholders have committed to avoiding competition with the company, ensuring no direct or indirect control over competing entities[110]. - The commitments made by the actual controller and major shareholders are effective and irrevocable during their tenure[117]. - The company commits to a proactive profit distribution policy, ensuring reasonable returns to shareholders while maintaining sustainable development[118]. Environmental Responsibility - The company has implemented strict measures for wastewater, solid waste, and noise management in compliance with environmental regulations[102][104]. - The company reported no administrative penalties related to environmental issues during the reporting period[104]. - The company has a focus on environmental responsibility, ensuring compliance with national environmental protection laws[101]. Shareholder Structure and Stock Management - The total number of shareholders is 74[190]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 64,969,560 shares, representing 33.37% of total shares[193]. - The company has a total of 6,002,000 shares under restricted conditions that will be tradable starting in 2024[197]. - The lock-up period for shares allocated to strategic investors is 12 months from the date of public offering on the Shanghai Stock Exchange[199].

Financial Performance - Operating revenue for the first quarter was RMB 656,230,414.60, a 201.37% increase compared to the same period last year[7] - Net profit attributable to shareholders increased by 221.52% year-on-year, amounting to RMB 316,215,504.78[7] - Basic earnings per share increased by 164.18% to RMB 1.77[7] - The company reported a total comprehensive income of ¥278.05 million for Q1 2021, compared to ¥62.08 million in Q1 2020, which is an increase of about 348%[29] - Operating profit for Q1 2021 reached ¥375.46 million, compared to ¥113.51 million in Q1 2020, indicating an increase of approximately 230%[28] - The company incurred a tax expense of ¥58.42 million in Q1 2021, compared to ¥15.15 million in Q1 2020, which is an increase of approximately 285%[28] Assets and Liabilities - Total assets increased by 122.09% year-on-year, reaching RMB 4,174,307,922.64[7] - The company's total assets as of March 31, 2021, amounted to RMB 3,686,735,980.88, up from RMB 1,582,916,525.82 at the end of the previous year[19] - Total liabilities decreased to ¥574,686,167.33 in Q1 2021 from ¥596,398,384.73 in Q4 2020, reflecting a reduction of approximately 3.7%[25] - The company's equity increased to ¥3,649,959,197.74 in Q1 2021, up from ¥1,438,570,779.29 in Q4 2020, marking an increase of around 153.5%[25] Cash Flow - Cash flow from operating activities rose by 29.88% to RMB 179,287,670.20[7] - The net cash flow from operating activities was ¥179,287,670.20, up from ¥138,044,205.22 in the same period last year, reflecting a growth of 29.8%[32] - The company reported cash inflow from operating activities of ¥635,207,144.40, a significant increase of 184.1% compared to ¥224,026,524.37 in Q1 2020[32] - Total cash inflow from financing activities reached ¥1,958,830,045.24, with no inflow recorded in Q1 2020[33] - The net cash flow from financing activities was ¥1,948,049,340.89, compared to no cash outflow in the previous year[33] - The company reported a net cash outflow from investing activities of ¥244,979,043.85, compared to ¥7,083,378.88 in Q1 2020, reflecting an increase of 3,457.5%[33] Research and Development - Research and development expenses accounted for 2.37% of operating revenue, down from 3.17%[8] - Research and development expenses rose by 125.57% to RMB 15,580,686.48, indicating the company's commitment to innovation and technology development[15] - Research and development expenses for Q1 2021 totaled ¥15.58 million, compared to ¥6.91 million in Q1 2020, marking an increase of approximately 125%[28] Shareholder Information - The top shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., holds 33.37% of the shares[11] - The total number of shareholders at the end of the reporting period was not specified[9] Inventory and Operating Costs - The total inventory increased by 122.91% to RMB 293,631,918.12, attributed to increased stockpiling due to the ongoing COVID-19 pandemic[15] - The company's gross profit margin increased, with operating costs rising by 303.95% to RMB 182,927,434.73, reflecting the revenue growth[15] - The total operating costs for Q1 2021 were ¥276.84 million, up from ¥101.10 million in Q1 2020, indicating a rise of about 174%[28] Future Outlook - The company has not indicated any significant changes in its future outlook or guidance for the upcoming periods[16]

Financial Performance - The net profit attributable to shareholders for 2020 was RMB 932,009,443.50, representing a year-on-year increase [6]. - The proposed cash dividend is RMB 16 per 10 shares, totaling RMB 311,526,960, which accounts for 33.43% of the net profit [6]. - As of December 31, 2020, the company's distributable profits amounted to RMB 883,440,108.39 [6]. - The company's operating revenue for 2020 reached ¥2,052,141,874.39, representing a 692.72% increase compared to ¥258,872,522.24 in 2019 [25]. - The net profit attributable to shareholders for 2020 was ¥932,009,443.50, a significant increase of 1,708.96% from ¥51,521,833.30 in the previous year [25]. - The net cash flow from operating activities for 2020 was ¥1,141,796,462.48, an increase of 1,389.41% compared to ¥76,660,805.72 in 2019 [25]. - The total assets at the end of 2020 amounted to ¥1,879,571,653.56, reflecting a 192.80% increase from ¥641,930,146.52 at the end of 2019 [25]. - The net assets attributable to shareholders increased to ¥1,462,598,582.88, a 155.77% rise from ¥571,843,209.21 in 2019 [25]. - The company's basic earnings per share (EPS) increased by 1,722.86% year-on-year, reaching 6.38 CNY per share in 2020 compared to 0.35 CNY in 2019 [26]. - The weighted average return on equity (ROE) rose by 82.39 percentage points to 91.62% in 2020, reflecting substantial profit growth [26]. Research and Development - The company has been actively involved in the research and development of new technologies and products related to nucleic acid testing and diagnostics [24]. - The R&D expenditure as a percentage of operating income decreased by 6.49 percentage points to 2.55% in 2020 [26]. - The company achieved a significant increase in R&D investment, totaling ¥52,425,072.12, which represents a growth of 123.99% compared to the previous year [62]. - The total R&D investment accounted for 2.55% of the operating revenue, a decrease of 6.49 percentage points from the previous year [62]. - The company has developed multiple core technologies, including automated nucleic acid extraction technology and high-throughput sequencing sample preprocessing technology, which enhance efficiency and precision in clinical testing [55][57]. - The company has developed a patented method for preparing high magnetic content, monodisperse magnetic beads, which improves nucleic acid extraction efficiency [54]. - The company has developed multiple nucleic acid extraction and detection instruments, addressing industry challenges such as complexity and time consumption [48]. Market Expansion and Strategy - The company is focused on expanding its market presence and enhancing its product offerings in the biotechnology sector [24]. - The company aims to leverage its strong financial performance to pursue strategic acquisitions and partnerships in the healthcare industry [24]. - The company has established a strong customer base in the HPV field, including top hospitals such as Peking Union Medical College Hospital and Shanghai Ruijin Hospital [47]. - The company aims to expand its market presence by addressing the complexities and time-consuming nature of traditional molecular diagnostic technologies [38]. - The company plans to enhance R&D investment to strengthen existing product technology and develop new products, including blood screening nucleic acid test kits and tumor early screening gene test kits [134]. - The company intends to improve internal controls and quality management to ensure product reliability and stability [137]. - The company will optimize its service and management of the distributor network to enhance technical support and responsiveness to market information [135]. Compliance and Governance - The report includes a standard unqualified audit opinion from Zhonghui Certified Public Accountants [6]. - The company does not have any special arrangements for corporate governance [10]. - The company has not violated decision-making procedures for external guarantees [10]. - The company has committed to avoiding related party transactions and competition, aimed at protecting shareholder interests [150][151]. - The company will strictly adhere to the profit distribution policy approved at the third extraordinary general meeting of shareholders in 2020, ensuring reasonable returns to shareholders while maintaining sustainable development [158]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation measures in the report [5]. - The company faces risks related to core technology leakage, which could impact its competitive edge in the molecular diagnostics industry [86]. - The company is exposed to market competition risks, particularly from multinational corporations that dominate the high-end medical market [89]. - The company must navigate potential price declines for its products as competition increases and regulatory changes occur [90]. - The company faces risks related to the sustainability of high growth due to the COVID-19 pandemic and potential changes in international trade policies affecting imported raw materials [96][95]. Product Development and Certifications - The company has developed over 400 types of molecular diagnostic products, covering most legally mandated infectious diseases in China [36]. - The company has received multiple international certifications for its COVID-19 test kits, including EU CE certification and inclusion in the WHO emergency use list [26]. - The company’s COVID-19 nucleic acid test kits have been certified by multiple international authorities and are included in the WHO Emergency Use Listing, with sales to over 80 countries and regions [80]. - The company has launched several automated nucleic acid extraction instruments and has obtained product registration certificates for these devices [75]. - The company’s HPV products have received CFDA/NMPA and EU CE certifications, demonstrating a strong technological advantage in the HPV testing field [46]. Employee and Talent Management - The total number of employees increased to 289, up by 58 from the end of the previous year, indicating a focus on talent development [85]. - The company has a total of 109 R&D personnel, accounting for 37.72% of the total workforce, with an average salary of RMB 125,438.15 [71]. - The company emphasizes the importance of maintaining a stable technical talent team to ensure ongoing technological leadership and core competitiveness [88]. - The company is committed to maintaining a competitive compensation and incentive mechanism to attract and retain high-end talent [136]. Financial Management and Investments - The company has invested a total of RMB 29,165 million, with RMB 5,144.09 million invested in the current period, and a cumulative investment of RMB 8,331.67 million [69]. - The company plans to increase its stake in Sanyou Biological from 14.01% to 19.5029% through a cash investment of ¥20 million [125]. - The company will implement a fundraising management system to ensure the legal and compliant use of raised funds, protecting the interests of investors, especially minority shareholders [199]. - The company will actively manage the raised funds in a dedicated account to ensure proper usage and compliance with regulations [199].